How to buy Shattuck Labs stock | $19.28

Shattuck Labs Inc is a biotechnology business based in the US. Shattuck Labs shares (STTK) are listed on the NASDAQ and all prices are listed in US Dollars. Shattuck Labs employs 59 staff and has a trailing 12-month revenue of around 0.00.

Shattuck Labs stock price (NASDAQ: STTK)

Use our graph to track the performance of STTK stocks over time.

Shattuck Labs shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$19.28
52-week range	$17.15 - $60.52
50-day moving average	$19.89
200-day moving average	$24.88
Wall St. target price	$48.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.82

Buy Shattuck Labs shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Shattuck Labs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shattuck Labs price performance over time

Historical closes compared with the close of $19.28 from 2021-10-21

1 week (2021-10-15)	-0.26%
1 month (2021-09-22)	1.80%
3 months (2021-07-22)	-16.14%
6 months (2021-04-22)	-35.39%

1 year (2020-10-22)	-11.40%
2 years (2019-10-18)	N/A
3 years (2018-10-18)	N/A
5 years (2016-10-18)	N/A

Shattuck Labs financials

Revenue TTM	$1.8 million
Gross profit TTM	$-27,018,000
Return on assets TTM	-15.85%
Return on equity TTM	-29.91%
Profit margin	0%
Book value	$6.58
Market capitalisation	$814.2 million

TTM: trailing 12 months

Shorting Shattuck Labs shares

There are currently 1.8 million Shattuck Labs shares held short by investors – that's known as Shattuck Labs's "short interest". This figure is 4.7% up from 1.7 million last month.

There are a few different ways that this level of interest in shorting Shattuck Labs shares can be evaluated.

Shattuck Labs's "short interest ratio" (SIR)

Shattuck Labs's "short interest ratio" (SIR) is the quantity of Shattuck Labs shares currently shorted divided by the average quantity of Shattuck Labs shares traded daily (recently around 204214.35132032). Shattuck Labs's SIR currently stands at 8.71. In other words for every 100,000 Shattuck Labs shares traded daily on the market, roughly 8710 shares are currently held short.

To gain some more context, you can compare Shattuck Labs's short interest ratio against those of similar companies.

• Bristol-Myers Squibb Company (BMY.US): 1.96
• Exact Sciences Corporation (EXAS.US): 8.01
• Moderna (MRNA.US): 1.06

However Shattuck Labs's short interest can also be evaluated against the total number of Shattuck Labs shares, or, against the total number of tradable Shattuck Labs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Shattuck Labs's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Shattuck Labs shares in existence, roughly 40 shares are currently held short) or 0.0763% of the tradable shares (for every 100,000 tradable Shattuck Labs shares, roughly 76 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Shattuck Labs.

Find out more about how you can short Shattuck Labs stock.

Shattuck Labs share dividends

We're not expecting Shattuck Labs to pay a dividend over the next 12 months.

You may also wish to consider:

• Bristol-Myers Squibb Company (BMY.US) (3.33% forward annual dividend yield)

Shattuck Labs overview

Shattuck Labs, Inc. , a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas. .

Frequently asked questions

What percentage of Shattuck Labs is owned by insiders or institutions?
Currently 23.106% of Shattuck Labs shares are held by insiders and 62.656% by institutions. How many people work for Shattuck Labs?
Latest data suggests 59 work at Shattuck Labs. When does the fiscal year end for Shattuck Labs?
Shattuck Labs's fiscal year ends in December. Where is Shattuck Labs based?
Shattuck Labs's address is: 1018 West 11th Street, Austin, TX, United States, 78703 What is Shattuck Labs's ISIN number?
Shattuck Labs's international securities identification number is: US82024L1035